Publications by authors named "Akitomo Inoue"
Effective therapeutic strategies for epithelioid sarcoma (EpS), a high-grade soft tissue sarcoma characterized by loss of integrase interactor 1 (INI1), have not yet been developed. The present study therefore investigated the association between INI1 loss and upregulation of the aurora kinase A (AURKA)/polo-like kinase 1 (PLK1)/cell division cycle 25C (CDC25C) axis, as well as the therapeutic relevance of this axis in EpS. Notably, our findings showed that the reintroduction of INI1 in VA-ES-BJ cells significantly reduced proliferation, mitigated tumorigenicity, and negatively regulated the expression of AURKA and its downstream effectors, as well as the activation of PLK1 and CDC25C.
View Article and Find Full Text PDFArticle Synopsis
- Osteosarcoma exhibits distinct genetic features between younger and elderly patients, influencing their treatment responses.
- Genetic analysis of 204 patients revealed specific mutations associated with age, indicating that younger patients tend to have alterations like CCNE1 and MYC, while older patients show changes like CDK4 and MDM2.
- The study concludes that understanding these genetic differences could enhance chemotherapy selection and treatment strategies for osteosarcoma, advocating for the early use of cancer genome profiling.
Article Synopsis
- Retroperitoneal dedifferentiated liposarcoma has a high recurrence rate, and this study seeks to identify effective surgical treatment strategies for recurrent cases.
- Analysis of 118 patients showed that the first and second surgeries significantly improved overall survival, while no major benefits were seen after a third surgery.
- Prognosis is influenced by tumor malignancy level, with low-grade tumors having better outcomes post-surgery compared to high-grade malignancies, suggesting careful consideration is needed before repeated surgeries.
Synovial sarcoma (SS), a rare subtype of soft-tissue sarcoma distinguished by expression of the fusion gene SS18-SSX, predominantly affects the extremities of young patients. Existing anticancer drugs have limited efficacy against this malignancy, necessitating the development of innovative therapeutic approaches. Given the established role of SS18-SSX in epigenetic regulation, we focused on bromodomain and extra-terminal domain protein (BET) inhibitors and epigenetic agents.
View Article and Find Full Text PDFArticle Synopsis
- Clear cell sarcoma (CCS) is a rare and aggressive cancer with no effective treatment, driven by a fusion gene that researchers targeted in this study.
- High-throughput drug screening identified vorinostat, a histone deacetylase inhibitor, as effective in reducing the fusion gene’s expression, though it only slightly altered the chromatin structure around the gene.
- Combining vorinostat with the BRD4 inhibitor JQ1 showed a synergistic effect in suppressing CCS cell proliferation, highlighting a new therapeutic strategy for treating tumors linked to fusion genes.
Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that rarely metastasizes but lacks effective systemic therapy once it propagates. In some reports, high interleukin-6 (IL-6) production promotes tumor growth by autocrine stimulation and tocilizumab, an IL-6 receptor antagonist, can control AFH growth. Here, we present a case report on a patient with local recurrence and distant lymph node metastasis of AFH treated with tocilizumab.
View Article and Find Full Text PDFThe number of studies on bone metastasis (BM) from gastric cancer (GC) is currently limited. Therefore, the aim of the present study was to investigate the characteristics, skeletal-related events (SREs) and prognosis of GC in patients with BMs. Data from 60 patients with BMs from GC were retrospectively retrieved and patient-, tumor- and BM-related characteristics were analyzed.
View Article and Find Full Text PDF